Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions Journal Article
| Authors: | Mondaca, S.; Lebow, E. S.; Namakydoust, A.; Razavi, P.; Reis-Filho, J. S.; Shen, R.; Offin, M.; Tu, H. Y.; Murciano-Goroff, Y.; Xu, C.; Makhnin, A.; Martinez, A.; Pavlakis, N.; Clarke, S.; Itchins, M.; Lee, A.; Rimner, A.; Gomez, D.; Rocco, G.; Chaft, J. E.; Riely, G. J.; Rudin, C. M.; Jones, D. R.; Li, M.; Shaffer, T.; Hosseini, S. A.; Bertucci, C.; Lim, L. P.; Drilon, A.; Berger, M. F.; Benayed, R.; Arcila, M. E.; Isbell, J. M.; Li, B. T. |
| Article Title: | Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions |
| Abstract: | Objectives: Liquid biopsy for plasma circulating tumor DNA (ctDNA) next-generation sequencing (NGS) can detect ALK fusions, though data on clinical utility of this technology in the real world is limited. Materials and Methods: Patients with lung cancer without known oncogenic drivers or who had acquired resistance to therapy (n = 736) underwent prospective plasma ctDNA NGS. A subset of this cohort (n = 497) also had tissue NGS. We evaluated ALK fusion detection, turnaround time (TAT), plasma and tissue concordance, matching to therapy, and treatment response. Results: ctDNA identified an ALK fusion in 21 patients (3%) with a variety of breakpoints and fusion partners, including EML4, CLTC, and PON1, a novel ALK fusion partner. TAT for ctDNA NGS was shorter than tissue NGS (10 vs. 20 days; p < 0.001). Among ALK fusions identified by ctDNA, 93% (13/14, 95% CI 66%–99%) were concordant with tissue evaluation. Among ALK fusions detected by tissue NGS, 54% (13/24, 95% CI 33%–74%) were concordant with plasma ctDNA. ctDNA matched patients to ALK-directed therapy with subsequent clinical response, including four patients matched on the basis of ctDNA results alone due to inadequate or delayed tissue testing. Serial ctDNA analysis detected MET amplification (n = 2) and ALK G1202R mutation (n = 2) as mechanisms of acquired resistance to ALK-directed therapy. Conclusion: Our findings support a complementary role for ctDNA in detection of ALK fusions and other alterations at diagnosis and therapeutic resistance settings. © 2021 Elsevier B.V. |
| Keywords: | next generation sequencing; circulating tumor dna; alk fusion; liquid biopsy |
| Journal Title: | Lung Cancer |
| Volume: | 159 |
| ISSN: | 0169-5002 |
| Publisher: | Elsevier Ireland Ltd. |
| Date Published: | 2021-09-01 |
| Start Page: | 66 |
| End Page: | 73 |
| Language: | English |
| DOI: | 10.1016/j.lungcan.2021.06.018 |
| PROVIDER: | scopus |
| PUBMED: | 34311346 |
| PMCID: | PMC8594131 |
| DOI/URL: | |
| Notes: | Article -- Erratum issued, see DOI: 10.1016/j.lungcan.2021.09.016 -- Export Date: 1 September 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work